PT110526B - Anticorpo, fragmento funcional ou sonda do mesmo contra antigénios tumorais - Google Patents

Anticorpo, fragmento funcional ou sonda do mesmo contra antigénios tumorais Download PDF

Info

Publication number
PT110526B
PT110526B PT110526A PT11052618A PT110526B PT 110526 B PT110526 B PT 110526B PT 110526 A PT110526 A PT 110526A PT 11052618 A PT11052618 A PT 11052618A PT 110526 B PT110526 B PT 110526B
Authority
PT
Portugal
Prior art keywords
antibody
probe
functional fragment
amino acid
same against
Prior art date
Application number
PT110526A
Other languages
English (en)
Portuguese (pt)
Other versions
PT110526A (pt
Inventor
Alexandra Quintela Videira Paula
Manuel Mendes Novo Carlos
Raquel Rodrigues Loureiro Liliana
Adelaide Do Rosário Carrascal Mylene
Alexandre Ribeiro De Castro Ferreira José
Angelina De Sá Palma Maria
Lara Santos Lúcio
Carlos Oliveira Lima Luís
Chai Wengang
Bachmann Michael
Original Assignee
Univ Nova De Lisboa
Inst Portugues De Oncologia Do Porto Fg Epe
Helmoholtz Zentrum Dresden Rossendorf Institute Of Radiopharmaceutical Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nova De Lisboa, Inst Portugues De Oncologia Do Porto Fg Epe, Helmoholtz Zentrum Dresden Rossendorf Institute Of Radiopharmaceutical Cancer Res filed Critical Univ Nova De Lisboa
Priority to PT110526A priority Critical patent/PT110526B/pt
Priority to AU2019211035A priority patent/AU2019211035B2/en
Priority to SG11202006897VA priority patent/SG11202006897VA/en
Priority to MX2020007828A priority patent/MX2020007828A/es
Priority to CA3089300A priority patent/CA3089300A1/en
Priority to KR1020207024660A priority patent/KR102933657B1/ko
Priority to US16/964,900 priority patent/US11353460B2/en
Priority to IL276208A priority patent/IL276208B1/en
Priority to JP2020560859A priority patent/JP7324777B2/ja
Priority to EA202091760A priority patent/EA202091760A1/ru
Priority to BR112020014931-4A priority patent/BR112020014931A2/pt
Priority to EP19702492.0A priority patent/EP3743726B1/en
Priority to PCT/PT2019/000001 priority patent/WO2019147152A1/en
Priority to CN201980022395.6A priority patent/CN113287018B/zh
Publication of PT110526A publication Critical patent/PT110526A/pt
Priority to ZA2020/05023A priority patent/ZA202005023B/en
Publication of PT110526B publication Critical patent/PT110526B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5756—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumour-associated glycolinkage [TAG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/91—Cell lines ; Processes using cell lines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
PT110526A 2018-01-26 2018-01-26 Anticorpo, fragmento funcional ou sonda do mesmo contra antigénios tumorais PT110526B (pt)

Priority Applications (15)

Application Number Priority Date Filing Date Title
PT110526A PT110526B (pt) 2018-01-26 2018-01-26 Anticorpo, fragmento funcional ou sonda do mesmo contra antigénios tumorais
IL276208A IL276208B1 (en) 2018-01-26 2019-01-17 Antibody l2a5 or a functional fragment thereof against tumor antigens
JP2020560859A JP7324777B2 (ja) 2018-01-26 2019-01-17 腫瘍抗原に対するｌ２ａ５抗体またはその機能的断片
MX2020007828A MX2020007828A (es) 2018-01-26 2019-01-17 Anticuerpo, fragmento funcional o sonda del mismo contra antigenos tumorales.
CA3089300A CA3089300A1 (en) 2018-01-26 2019-01-17 Antibody, functional fragment or probe thereof against tumour antigens
KR1020207024660A KR102933657B1 (ko) 2018-01-26 2019-01-17 종양 항원에 대한 l2a5 항체, 그것의 기능적 단편 또는 그것의 프로브
US16/964,900 US11353460B2 (en) 2018-01-26 2019-01-17 L2A5 antibody or functional fragment thereof against tumour antigens
AU2019211035A AU2019211035B2 (en) 2018-01-26 2019-01-17 L2A5 antibody or functional fragment thereof against tumour antigens
SG11202006897VA SG11202006897VA (en) 2018-01-26 2019-01-17 L2a5 antibody or functional fragment thereof against tumour antigens
EA202091760A EA202091760A1 (ru) 2018-01-26 2019-01-17 Антитело, его функциональный фрагмент или зонд против опухолевых антигенов
BR112020014931-4A BR112020014931A2 (pt) 2018-01-26 2019-01-17 Anticorpo, fragmento funcional ou sonda do mesmo contra antígenos tumorais
EP19702492.0A EP3743726B1 (en) 2018-01-26 2019-01-17 L2a5 antibody or functional fragment thereof against tumour antigens
PCT/PT2019/000001 WO2019147152A1 (en) 2018-01-26 2019-01-17 L2a5 antibody or functional fragment thereof against tumour antigens
CN201980022395.6A CN113287018B (zh) 2018-01-26 2019-01-17 抗肿瘤抗原的l2a5抗体或其功能性片段
ZA2020/05023A ZA202005023B (en) 2018-01-26 2020-08-13 L2a5 antibody or functional fragment thereof against tumour antigens

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PT110526A PT110526B (pt) 2018-01-26 2018-01-26 Anticorpo, fragmento funcional ou sonda do mesmo contra antigénios tumorais

Publications (2)

Publication Number Publication Date
PT110526A PT110526A (pt) 2019-07-26
PT110526B true PT110526B (pt) 2021-02-04

Family

ID=65244573

Family Applications (1)

Application Number Title Priority Date Filing Date
PT110526A PT110526B (pt) 2018-01-26 2018-01-26 Anticorpo, fragmento funcional ou sonda do mesmo contra antigénios tumorais

Country Status (14)

Country Link
US (1) US11353460B2 (https=)
EP (1) EP3743726B1 (https=)
JP (1) JP7324777B2 (https=)
CN (1) CN113287018B (https=)
AU (1) AU2019211035B2 (https=)
BR (1) BR112020014931A2 (https=)
CA (1) CA3089300A1 (https=)
EA (1) EA202091760A1 (https=)
IL (1) IL276208B1 (https=)
MX (1) MX2020007828A (https=)
PT (1) PT110526B (https=)
SG (1) SG11202006897VA (https=)
WO (1) WO2019147152A1 (https=)
ZA (1) ZA202005023B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022195797A1 (ja) * 2021-03-18 2022-09-22 国立大学法人弘前大学 末端シアル酸残基がα２，６結合でガラクトースに結合した糖鎖に特異的に結合するモノクローナル抗体、及び、末端シアル酸残基がα２，６結合でガラクトースに結合した糖鎖の測定方法
WO2022224242A1 (en) * 2021-04-20 2022-10-27 Ramot At Tel-Aviv University Ltd. Humanized anti-sialyl-tn glycan antibodies and uses thereof
GB2619976A (en) * 2022-06-24 2023-12-27 Cellmabs S A Humanised antibodies or functional fragments thereof against tumour antigens
CN121219019A (zh) 2023-05-05 2025-12-26 百欧恩泰欧洲股份公司 用于增强靶向癌症相关抗原的采用新型连接子-有效载荷系统的抗体药物偶联物
WO2026057354A1 (en) * 2024-09-10 2026-03-19 Invox Pharma Limited Anti-sialyl-tn antigen-binding proteins

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429295B1 (en) * 1998-02-05 2002-08-06 Centro De Inmunologia Molecular (Cim) Monoclonal antibody which recognizes the oligosaccharide N-glycolylated-galactose-glucose sialic acid in malignant tumors, and composition containing it
JP2008195666A (ja) * 2007-02-14 2008-08-28 Japan Science & Technology Agency ２−６シアリル６−スルホ糖鎖に対する抗体
CA2743032A1 (en) * 2007-11-09 2009-05-14 Suomen Punainen Risti, Veripalvelu Human monoclonal antibodies directed to sialyl lewis c, sialyl tn and n-glycolylneuraminic acid epitopes and a method of analysis of stem cells comprising said epitopes
WO2016057916A1 (en) * 2014-10-10 2016-04-14 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US20160184450A1 (en) * 2004-06-23 2016-06-30 Children's Hospital & Research Center Oakland DE-N-Acetyl Sialic Acid Antigens, Antibodies Thereto, and Methods of Use in Cancer Therapy

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
DE68922806T2 (de) * 1988-03-11 1996-02-29 Biomembrane Inst Monoklonale antikörper und herstellung eines impfstoffes gegen menschliche krebsantigene durch immunisierung mit menschlichem und tierischem mucin und mit synthetischen gluciden-trägerkonjugaten.
WO1995029927A2 (en) 1994-05-02 1995-11-09 Biomira, Inc. Process for preparation of glycosides of tumor-associated carbohydrate antigens
WO1998046246A1 (en) 1997-04-16 1998-10-22 Sloan-Kettering Institute For Cancer Research α-O-LINKED GLYCOCONJUGATES WITH CLUSTERED (2,6)-ST EPITOPES, METHODS OF PREPARATION AND USES THEREOF
JP3809277B2 (ja) 1998-03-05 2006-08-16 生化学工業株式会社 Ｎ−アセチルグルコサミン−６−ｏ−硫酸基転移酵素のポリペプチド及びそれをコードするｄｎａ
GB9917012D0 (en) 1999-07-20 1999-09-22 Pharmacia & Upjohn Spa Combined preparations comprising antitumor agents
EP2261255A1 (en) 2003-07-15 2010-12-15 The Regents of The University of California Methods for purifying sialic acid-specific antibodies and composition comprising affinity-purified antibodies
AU2007304590A1 (en) 2006-10-04 2008-04-10 Cancer Research Technology Limited Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies
EP2014302A1 (en) 2007-07-12 2009-01-14 Institut Curie An antibody specific for the Tn antigen for the treatment of cancer
EP2287202A1 (en) 2009-08-07 2011-02-23 Dublin City University Anti-sialic acid antibody molecules
EP2524233A4 (en) 2010-01-15 2013-07-31 Univ California COMPOSITIONS AND METHOD FOR DETECTING CANCER
US9796785B2 (en) 2013-05-02 2017-10-24 National Institute Of Advanced Industrial Science And Technology Monoclonal antibody recognizing sialylated sugar chains
WO2014191128A1 (en) 2013-05-29 2014-12-04 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
AU2014332442B2 (en) 2013-08-26 2019-12-19 Biontech Research And Development, Inc. Nucleic acids encoding human antibodies to Sialyl-Lewis
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
WO2017040529A1 (en) * 2015-08-31 2017-03-09 Bluebird Bio, Inc. Anti-sialyl tn chimeric antigen receptors
WO2018217116A1 (en) * 2017-05-25 2018-11-29 Instituto De Patologia E Imunologia Da Universidade Do Porto (Ipatimup) Detection and isolation of cancer cells from body fluids based on a glycosylation pattern and methods of use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429295B1 (en) * 1998-02-05 2002-08-06 Centro De Inmunologia Molecular (Cim) Monoclonal antibody which recognizes the oligosaccharide N-glycolylated-galactose-glucose sialic acid in malignant tumors, and composition containing it
US20160184450A1 (en) * 2004-06-23 2016-06-30 Children's Hospital & Research Center Oakland DE-N-Acetyl Sialic Acid Antigens, Antibodies Thereto, and Methods of Use in Cancer Therapy
JP2008195666A (ja) * 2007-02-14 2008-08-28 Japan Science & Technology Agency ２−６シアリル６−スルホ糖鎖に対する抗体
CA2743032A1 (en) * 2007-11-09 2009-05-14 Suomen Punainen Risti, Veripalvelu Human monoclonal antibodies directed to sialyl lewis c, sialyl tn and n-glycolylneuraminic acid epitopes and a method of analysis of stem cells comprising said epitopes
WO2016057916A1 (en) * 2014-10-10 2016-04-14 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LOUREIRO ET AL.: "Challenges in Antibody Development against Tn and Sialyl-Tn Antigens", BIOMOLECULES, VOL., 1 January 0005 (0005-01-01) *

Also Published As

Publication number Publication date
CN113287018A (zh) 2021-08-20
IL276208B1 (en) 2026-02-01
CN113287018B (zh) 2025-10-28
EP3743726B1 (en) 2024-06-12
EA202091760A1 (ru) 2020-11-23
IL276208A (en) 2020-09-30
AU2019211035A1 (en) 2020-08-06
WO2019147152A1 (en) 2019-08-01
PT110526A (pt) 2019-07-26
JP2021516254A (ja) 2021-07-01
CA3089300A1 (en) 2019-08-01
KR20210005546A (ko) 2021-01-14
SG11202006897VA (en) 2020-08-28
EP3743726A1 (en) 2020-12-02
JP7324777B2 (ja) 2023-08-10
AU2019211035B2 (en) 2025-08-14
BR112020014931A2 (pt) 2020-12-08
US11353460B2 (en) 2022-06-07
MX2020007828A (es) 2020-11-24
US20210033616A1 (en) 2021-02-04
ZA202005023B (en) 2022-01-26

Similar Documents

Publication Publication Date Title
PT110526B (pt) Anticorpo, fragmento funcional ou sonda do mesmo contra antigénios tumorais
CY1124435T1 (el) Νουκλεικα οξεα που κωδικοποιουν ανθρωπινα αντισωματα σε sialyl-lewis α
BR112019022515A2 (pt) Agentes de anticorpo direcionados contra o gene 3 de ativação linfocitária (lag-3) e usos dos mesmos
BR112018075737A2 (pt) anticorpo, composição, célula isolada, e, métodos para tratar câncer ou infecção em um paciente e para detectar expressão de pd-l1 em uma amostra.
PH12020550650A1 (en) Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof
CY1121900T1 (el) Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2
BR112020006248A8 (pt) Anticorpo anti-bcma com alta afinidade para bcma, polinucleotídeo, vetor de expressão, célula hospedeira, método para produção do dito anticorpo, composição farmacêutica compreendendo o mesmo e uso do anticorpo para prevenção ou tratamento de câncer
CY1111283T1 (el) Μορια με παρατεταμενες ημι-περιοδους ζωης, συνθεσεις και χρησεις εξ αυτων
BR112016030686A2 (pt) anticorpos anti tau humanizados
NO20056236L (no) Behandling med anti-VEGF-antistoffer
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
EA201891435A1 (ru) Гуманизированные моноклональные антитела, моноклональные антитела мыши или химерные моноклональные антитела против cd47
PE20071055A1 (es) Anticuerpos anti mn
NZ594682A (en) Fully human antibodies specific to cadm1
PE20150023A1 (es) Proteinas de union a antigeno st2
CO2021011944A2 (es) Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer
BR112018075434A2 (pt) anticorpo isolado ou fragmento de ligação de antígeno do mesmo, composição farmacêutica, e, métodos para tratar câncer e para modular resposta imune antitumor.
CY1116646T1 (el) Αντικαρκινικη πρωτεϊνη συντηξης
BR112021016791A2 (pt) Proteínas de ligação de antígenos que se ligam a bcma
BR112022008653A2 (pt) Conjugado anticorpo-fármaco, método para tratar câncer, e, uso do conjugado anticorpo-fármaco
BR112021025077A2 (pt) Anticorpos anti-sortilina para uso em terapia
BR112023002455A2 (pt) Anticorpos fgfr3 e métodos de uso
MX2022000988A (es) Proteinas de union a antigeno anti-il13.
BR112022003635A2 (pt) Anticorpo anti-vsig4 ou fragmento de ligação ao antígeno e seu uso
BR112018014538A2 (pt) anticorpos monoclonais específicos para o antígeno piii de adenovírus humano (adv), produzidos e secretados por hibridomas celulares, úteis para detecção e diagnóstico de infecção por adv

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 20180508

FG3A Patent granted, date of granting

Effective date: 20210129